Concepedia

Carmen García-Duran

CG

Statistics

Publications

2

Citations

39

H-Index

2

Active since

2023

Affiliations

Vall d'Hebron Institute of Oncology(Current)

Vall d'Hebron Hospital Universitari

Carmen García-Duran is an author at Vall d'Hebron Institute of Oncology specializing in pharmacotherapy, cancer therapeutics, and clinical trials.

Top concepts

Publications per year

2023–2024

2

Publications

2

Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort.

Ana Oaknin, Lorena Fariñas-Madrid, Carmen García-Duran et al. · Journal of Clinical Oncology · 2023 · 25 citations

, , +19

Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study.

Frederik Marmé, Philipp Harter, Andrés Redondo et al. · Journal of Clinical Oncology · 2024 · 14 citations · Full text

, , +18

1–2 of 2